Gene therapy offers people with rare bleeding disorder a new level of freedom
(BPT) - -
Source: montanarightnow.com
Stay updated with breaking news from Coagulation Disorders Program. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
The U.S. Food and Drug Administration (FDA) has accepted for priority review the Biologics License Application (BLA) for efanesoctocog alfa (BIVV001) for the treatment of hemophilia A, a rare and life-threatening bleeding disorder. The target action date for the FDA decision is February 28, 2023. Sanofi and Sobi® ...
Monthly infusion vs on-demand bypassing agents effective in patients with or without inhibitors